Neuritogenic and neuroprotective properties of peptide agonists of the fibroblast growth factor receptor

Shizhong Li1, Elisabeth Bock, Vladimir Berezin

  • 1Protein Laboratory, Department of Neuroscience and Pharmacology, Panum Institute, University of Copenhagen, Copenhagen N, Denmark; E-Mails: li@sund.ku.dk (S.L.); bock@sund.ku.dk (E.B.).

Insights

Researchers identified novel peptide agonists that activate Fibroblast Growth Factor Receptors (FGFRs). These peptides mimic FGFs and NCAM, showing promise for neuroprotection and neuritogenesis in the nervous system.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Drug Discovery

Background:

  • Fibroblast Growth Factor Receptors (FGFRs) are crucial for nervous system development and maintenance.
  • FGFRs interact with ligands (FGFs) and cell adhesion molecules (CAMs) like NCAM.
  • These interactions mediate critical cellular events in the nervous system.

Purpose of the Study:

  • To review recently developed functional peptide agonists of FGFR.
  • To explore the therapeutic potential of these novel peptides.
  • To highlight peptides mimicking FGFs and NCAM for FGFR activation.

Main Methods:

  • Protein structure determination.
  • In silico modeling.
  • Biological studies to identify and characterize peptide agonists.

Main Results:

  • Identification of FGFR binding peptides derived from FGFs and NCAM.
  • Demonstration that these peptides mimic the neuritogenic and neuroprotective effects of native molecules.
  • Characterization of functional peptide agonists for FGFR.

Conclusions:

  • Novel peptide agonists targeting FGFRs have been developed.
  • These peptides exhibit therapeutic potential for nervous system disorders.
  • Further research into FGFR-targeting peptides could lead to new treatments.